Biosyent Inc V.RX

Return to Glory Days

[overnout]

MISSISSAUGA, Ontario, March 09, 2022 (GLOBE NEWSWIRE) --  BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today its financial results for the three and twelve months ended December 31, 2021. Key highlights include:  

• Fourth quarter (Q4) 2021 Net Revenues of $7,218,656 increased by 26% versus Q4 2020
• Full year (FY) 2021 Net Revenues of $28,618,218 increased by 28% versus FY 2020
• Q4 2021 Canadian Pharmaceutical Net Revenues of $6,466,381 increased by 20% versus Q4 2020
• FY 2021 Canadian Pharmaceutical Net Revenues of $25,780,275 increased by 21% versus FY 2020
• Q4 2021 International Pharmaceutical Net Revenues of $318,406 increased by 462% versus Q4 2020
• FY 2021 International Pharmaceutical Net Revenues of $1,623,723 increased by 621% versus FY 2020
• Q4 2021 EBITDA1 of $2,639,145 increased by 136% versus Q4 2020
• FY 2021 EBITDA1 of $8,783,726 increased by 57% versus FY 2020
• Q4 2021 Net Income After Taxes (NIAT) of $1,877,804 increased by 182% versus Q4 2020
• FY 2021 NIAT of $6,281,566 increased by 66% versus FY 2020
• Q4 2021 NIAT percentage to Net Revenues of 26% compares to 12% in Q4 2020
• FY 2021 NIAT percentage to Net Revenues of 22% compares to 17% in FY 2020
• Q4 2021 Fully Diluted EPS of $0.15 was $0.10 higher than Q4 2020 Fully Diluted EPS of $0.05
• FY 2021 Fully Diluted EPS of $0.49 was $0.20 higher than FY 2020 Fully Diluted EPS of $0.29
• As at December 31, 2021, the Company had cash, cash equivalents, and short-term investments totalling $28,211,670 as compared to $25,577,706 as at December 31, 2020 – a 10% increase
• Total Shareholders’ Equity increased by 18% to $31,554,926 at December 31, 2021 from $26,795,956 at December 31, 2020
• Return on Equity for the year ended December 31, 2021 was 21% as compared to 14% for the year ended December 31, 2020
• During FY 2021, repurchased a total of 180,950 common shares under a Normal Course Issuer Bid (NCIB) and a further 124,300 common shares repurchased to date in 2022

[lscfa]

Long time coming....     Revenue eps 2021 28,618,218 $0.49 2020 22,332,168 $0.29 2019 21,424,324 $0.31 2018

[theinvestor22]

Yup, that was quite a good quarter.  I can only imagine how well the company will do once they get full access to health care professionals once again.  Kudos to RX mgmt. And, I think a dividend is going to happen eventually.   Regular acquisitions in the pharma space have been too expensive for a very long time.  Their method of getting the rights to products at a

[lscfa]

Beat Bloom Burton's forecast of $26.9 mil rev, $7.9 mil ebitda, $0.39 eps.